<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17940501</article-id><article-id pub-id-type="pmc">2360436</article-id><article-id pub-id-type="pii">6603994</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603994</article-id><article-categories><subj-group subj-group-type="heading"><subject>Translational Therapeutics</subject></subj-group></article-categories><title-group><article-title>The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bruynzeel</surname><given-names>A M E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Niessen</surname><given-names>H W M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bronzwaer</surname><given-names>J G F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>van der Hoeven</surname><given-names>J J M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Berkhof</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bast</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>van der Vijgh</surname><given-names>W J F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>van Groeningen</surname><given-names>C J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Medical Oncology, 2 PK BR 010, VU University Medical Center</institution> De Boelelaan 1117, Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, VU University Medical Center</institution> Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff3"><label>3</label><institution>ICaR-VU, VU University Medical Center</institution> Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff4"><label>4</label><institution>Department of Cardiac Surgery, VU University Medical Center</institution> Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff5"><label>5</label><institution>Department of Cardiology, VU University Medical Center</institution> Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff6"><label>6</label><institution>Department of Clinical Epidemiology and Biostatistics, VU University Medical Center</institution> Amsterdam 1081 HV, <country>The Netherlands</country></aff><aff id="aff7"><label>7</label><institution>Department of Internal Medicine, Ziekenhuis Amstelland</institution> Amstelveen 1186 AM, <country>The Netherlands</country></aff><aff id="aff8"><label>8</label><institution>Department of Pharmacology and Toxicology, Faculty of Medicine, University of Maastricht</institution> Maastricht 6200 MD, <country>The Netherlands</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ame.bruynzeel@vumc.nl">ame.bruynzeel@vumc.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2007</year></pub-date><pub-date pub-type="collection"><day>16</day><month>10</month><year>2007</year></pub-date><pub-date pub-type="ppub"><day>22</day><month>10</month><year>2007</year></pub-date><volume>97</volume><issue>8</issue><fpage>1084</fpage><lpage>1089</lpage><history><date date-type="rev-recd"><day>16</day><month>08</month><year>2007</year></date><date date-type="accepted"><day>23</day><month>08</month><year>2007</year></date></history><copyright-statement>Copyright 2007, Cancer Research UK</copyright-statement><copyright-year>2007</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10&#x02009;min i.v. infusion of 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour.</p></abstract><kwd-group><kwd>monoHER</kwd><kwd>monohydroxyethylrutoside</kwd><kwd>doxorubicin</kwd><kwd>cardiotoxicity</kwd><kwd>clinical phase II study</kwd></kwd-group></article-meta></front><body><p>The anthracycline doxorubicin (DOX) is widely used in the treatment of several malignancies in adult and paediatric patients. Treatment with DOX is limited by a dose-dependent cardiotoxicity, which may lead to late side effects resulting in severe morbidity and mortality (<xref ref-type="other" rid="bib32">Steinherz <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib19">Lipshultz <italic>et al</italic>, 2005</xref>). Although the 5-year survival of childhood cancer has improved from 30 to 70&#x00025; in the last 40 years, the risk of death from cardiac events in these survivors is eight times higher than that in the normal population (<xref ref-type="other" rid="bib41">Wouters <italic>et al</italic>, 2005</xref>). Besides this, combining DOX with other anticancer drugs, for example, taxanes and trastuzumab, increases efficacy, but unfortunately also augments cardiotoxicity (<xref ref-type="other" rid="bib28">Seidman <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib23">Minotti <italic>et al</italic>, 2004</xref>).</p><p>Although the mechanism of DOX-induced cardiotoxicity is still not fully understood, a major role has been ascribed to the induction of free radicals (<xref ref-type="other" rid="bib15">Horenstein <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib16">Hrdina <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib42">Xu <italic>et al</italic>, 2001</xref>). The cardiomyocyte is particularly vulnerable to free radical injury because of properties such as a low antioxidant status (<xref ref-type="other" rid="bib10">Doroshow <italic>et al</italic>, 1980</xref>; <xref ref-type="other" rid="bib17">Iarussi <italic>et al</italic>, 2000</xref>). Presently, the cardioprotectant dexrazoxane is the only drug with proven efficacy (<xref ref-type="other" rid="bib8">Cvetkovic and Scott, 2005</xref>). A recent review recommended the use of dexrazoxane if the risk of cardiotoxicity is high. However, clinicians should weigh its cardioprotective effect against the risk of a possible decrease of antitumour activity (<xref ref-type="other" rid="bib38">Van Dalen <italic>et al</italic>, 2005</xref>). Preclinical experiments showed that the flavonoid 7-monohydroxyethylrutoside (monoHER) is a potential protective agent against DOX-induced cardiotoxicity without interfering with its antitumour activity (<xref ref-type="other" rid="bib36">Van Acker <italic>et al</italic>, 1997</xref>, <xref ref-type="other" rid="bib35">2000</xref>). Radical scavenging and iron chelating properties are the supposed mechanisms of action of monoHER (<xref ref-type="other" rid="bib13">Haenen <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib37">Van Acker <italic>et al</italic>, 1993</xref>). No serious side effects were observed in a clinical phase I study up to a dose of 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. At this dose, the pharmacokinetic end points were reached, that is, <italic>C</italic><sub>max</sub> and AUC<sup>&#x0221e;</sup> were comparable to those obtained in mice under protecting conditions. Therefore, this dose was evaluated in a phase II study (<xref ref-type="other" rid="bib40">Willems <italic>et al</italic>, 2006</xref>).</p><p>In the present study, we evaluated the cardioprotective properties of 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> monoHER given as a 10&#x02009;min i.v. infusion before DOX in patients with metastatic cancer. For the early sensitive and specific detection of DOX-induced cardiotoxicity, endomyocardial biopsies were taken (<xref ref-type="other" rid="bib22">Meinardi <italic>et al</italic>, 1999</xref>).</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patient selection</title><p>Patients with metastatic solid tumours were entered when they received a DOX-based chemotherapy regimen with a dosage of DOX&#x02a7e;50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> per cycle and an infusion duration &#x02a7d;1&#x02009;h. Patients had a WHO performance status of &#x02a7d;2 and a life expectancy of &#x02a7e;3 months. They also had adequate organ functions. Their left ventricular ejection fraction (LVEF), measured by multigated radionuclide angiography, was &#x0003e;50&#x00025;. Patients were excluded if they had received prior anthracyclines, had prior or actual cardiovascular disease or had prior radiotherapy to the mediastinum.</p><p>All patients gave written informed consent and the protocol was approved by the Medical Ethical Review Committee of the VU University Medical Center (VUMC). Patients were enrolled between September 2003 and March 2006.</p></sec><sec><title>Treatment</title><p>7-Monohydroxyethylrutoside was provided by Novartis Consumer Health (Nyon, Switzerland). The drug was formulated by the Department of Pharmacy, VUMC, Amsterdam as described before (<xref ref-type="other" rid="bib40">Willems <italic>et al</italic>, 2006</xref>). Formulated DOX (doxorubicin hydrochloride, 2&#x02009;mg&#x02009;ml<sup>&#x02212;1</sup>) was obtained from Pharmachemie B.V. (Haarlem, the Netherlands).</p><p>7-Monohydroxyethylrutoside was administered i.v. in 10&#x02009;min at a dose of 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> 60&#x02009;min before every DOX administration. If cardiotoxicity would be observed in the first three evaluable patients, administration according to this dosing scheme would be changed and a following patient would receive DOX infusion either immediately after monoHER (because in plasma and heart, <italic>C</italic><sub>max</sub> of monoHER is obtained immediately after the end of infusion; <xref ref-type="other" rid="bib1">Abou El Hassan <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib40">Willems <italic>et al</italic>, 2006</xref>) or with an interval of 2&#x02009;h (to give monoHER the opportunity to convert into an active metabolite, if any). If cardiotoxicity was maintained in both patients, then the study would be finished. If one of the two patients shows cardioprotection, then 10 additional patients will be treated with the protecting scheme.</p></sec><sec><title>Patient evaluation</title><p>Before starting, patients were evaluated by a full blood count, serum biochemistry including liver function tests, lactate dehydrogenase, and cholesterol. Risk factors for cardiovascular disease were also evaluated. An LVEF and an ECG were performed before entry into the study.</p><p>Every subsequent administration of monoHER and DOX was preceded by a full blood count, liver enzymes, serum creatinine and a routine 12-lead ECG. A complete blood count was also done 10 days after chemotherapy.</p><p>After a cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX, an endomyocardial biopsy was performed and the LVEF was measured. The latter was repeated at least 3 weeks after the last dose of DOX with a biopsy if possible. For logistic reasons, the biopsy of patient no. 8 was done after a cumulative dose of 375&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX.</p></sec><sec><title>Endomyocardial biopsy</title><p>During a left heart catheterisation, a 104&#x02009;cm, seven french biopsy forceps was used to obtain tissue from the left ventricle. Three to four specimens 0.5&#x02013;1&#x02009;mm in diameter were obtained. The specimens were fixed in 4&#x00025; buffered formaldehyde and prepared for electron microscopy.</p></sec><sec><title>Histological analysis and biopsy scores</title><p>After fixation in 4&#x00025; buffered formaldehyde, the heart tissue was post fixed in 1&#x00025; osmium tetroxide. The tissue was then dehydrated through a graded series of ethanol solutions of 70&#x02013;95&#x00025; and embedded in JB-4 Plus resin. Thereafter, 0.5&#x02013;3.0&#x02009;<italic>&#x003bc;</italic>m thick sections were cut with a glass knife. These semithin sections were processed for electron microscopy. Cardiomyocytes with &#x0003e;2 microvacuoles, macrovacuoles and&#x0002f;or loss of myofibrils were counted as deviant. The morphological grade determined from the specimens examined by electron microscopy was scored on a six-point scale previously described by <xref ref-type="other" rid="bib3">Billingham <italic>et al</italic> (1978)</xref> (<xref ref-type="other" rid="bib7">Bristow <italic>et al</italic>, 1982</xref>): in grade 0, cells are normal; in grade 1, 1.5, 2 and 2.5 deviant cells are &#x0003c;5, 5&#x02013;15, 16&#x02013;25 and 26&#x02013;35&#x00025;, respectively; in grade 3, cell damage is &#x0003e;35&#x00025;.</p></sec><sec><title>Off-study criteria</title><p>Patients went off study in case of progressive disease, a serious cardiac event or other events that precluded further treatment. Criteria described by <xref ref-type="other" rid="bib30">Shapiro <italic>et al</italic> (1999)</xref> were used for diagnosis of cardiac events. Episodes of cardiac dysfunction were characterised according to the NYHA functional classification (<xref ref-type="other" rid="bib28">Seidman <italic>et al</italic>, 2002</xref>).</p></sec><sec><title>Assessment of tumour response</title><p>Assessment of tumour response was carried out every 2&#x02013;3 cycles by CT scan, using standard ECOG criteria (<xref ref-type="other" rid="bib26">Oken <italic>et al</italic>, 1982</xref>).</p></sec><sec><title>Statistical analysis</title><p>This trial was an open-labelled, controlled study. We compared the data of our patients with those of 14 patients from the study of <xref ref-type="other" rid="bib34">Torti <italic>et al</italic> (1986)</xref> treated with a cumulative dose of DOX between 200 and 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> alone using the <italic>&#x003c7;</italic><sup>2</sup> test. Our hypothesis was that adding monoHER to DOX would eliminate its cardiotoxicity up to a cumulative dose of at least 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, which was the upper limit of the dose interval of DOX from Torti's patients. To achieve a power of 80&#x00025;, 11 patients would be required. This sample size was obtained when applying the <italic>&#x003c7;</italic><sup>2</sup> test with significance level 0.05 and assuming a response rate (i.e. no cardiac damage) in the experimental arm of 80&#x00025;. If at least five patients show DOX-induced damage, statistical significance cannot be achieved anymore and the study should be stopped.</p></sec></sec><sec><title>RESULTS</title><p>Eight patients meeting the inclusion criteria were enrolled (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Analysis of risk factors indicated that patient no. 6 was treated for hyperhomocysteinaemia. Two other patients had an elevated body mass index of 29.1 (no. 1) and 30.1 (no. 7), indicating overweight and obesity, respectively. Patient no. 2 had hyperlipidaemia (LDL of 6.3&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup>; normal values &#x02a7d;5.0). None of the other patients had risk factors for cardiovascular disease. All patients were classified as NYHA class <sup>2</sup> and had a performance status (WHO) &#x02a7d;2.</p><p>Five patients received a cumulative dose of &#x02a7e;300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX and underwent a biopsy. In the other three patients, DOX was discontinued before this dose, due to progressive disease.</p><p>Patient no. 3 received irradiation after he was operated for a parapharyngeal tumour with a modified radical neck dissection at his right site because of a malignant peripheral nerve sheet tumour. Both patient nos. 7 and 8 received postoperative irradiation after resection of the malignant fibrous histiocytoma in their right upper leg.</p><sec><title>Treatment with DOX preceded by monoHER</title><p>During monoHER infusion, two patients reported adverse events. One patient described a sensation of fullness in his stomach, which developed during infusion of monoHER and disappeared soon after the end of the infusion. The other patient experienced itching in the skin of the neck during monoHER infusion and disappearing rapidly after the infusion. Both patients experienced the events during each cycle. A causal relationship cannot be excluded. The other six patients did not experience adverse events.</p><p>None of the patients had a delay in receiving subsequent cycles of chemotherapy. As expected, all patients developed chemotherapy-related leukopaenia, which recovered before the start of the next cycle. No disturbances of liver enzymes and serum creatinine were noted.</p></sec><sec><title>Biopsy scores</title><p>The endomyocardial biopsy scores are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. After 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, the first three evaluable patients showed abnormalities consistent with DOX-induced cardiotoxicity, that is the presence of microvacuoles dominated (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In patient nos. 3 and 4, microvacuoles were present in 52 and 20&#x00025; of the cardiomyocytes, respectively. In patient no. 6, 33&#x00025; of the cardiomyocytes had &#x0003e;2 small vacuoles per cardiomyocyte. Because each of the first three evaluable patients showed cardiotoxicity, it was decided to stop this dosing scheme. The time interval between monoHER and DOX administration was changed and patient no. 7 received DOX immediately after monoHER. In the biopsy of this patient, microvacuolisation was observed in 60&#x00025; of the cardiomyocytes. After this result, the interval was changed again and patient no. 8 received DOX 2&#x02009;h after monoHER administration. In this patient, microvacuolisation was detected in 49&#x00025; of the cardiomyocytes. After these results, the study had to be considered negative, because no cardioprotective effect of monoHER was observed in the five patients.</p><p>Second biopsies were also taken after 450&#x02013;480&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of DOX in two patients (<xref rid="tbl3" ref-type="table">Table 3</xref>). The score of patient no. 4 had increased from 2.0 to 2.5, whereas the score of patient no. 3 remained 3. Striking was the increase in loss of myofibrils in addition to the microvacuoles observed in the cardiomyocytes after 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Ten months after his last cycle of DOX, patient no. 4 underwent a third biopsy. This time, the cardiomyocytes showed recuperation of myofibrils, whereas the number of abnormal cardiac cells (microvacuolisation) was less than that in the first two biopsies (score 2).</p><p>No complications occurred during the seven biopsy procedures in the first four patients. However, the last patient (no. 8) developed a small pericardial effusion after the biopsy. This was preceded by chest pain and transient supraventricular rhythm disturbances. These sequelae disappeared within a few days and after a week she recovered and received the sixth cycle of DOX.</p></sec><sec><title>Monitoring and evaluation of cardiac function</title><p>In all patients, the ECG remained unchanged during therapy and no cardiac dysfunction occurred.</p><p>The five patients who received at least 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX started with an LVEF &#x0003e;50&#x00025; (<xref rid="tbl2" ref-type="table">Table 2</xref>). After 300&#x02013;375&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX, the LVEF decreased in 4 out of 5 patients. This decrease was not related with the biopsy score or the time interval between monoHER and DOX infusions. Unfortunately, no information on the LVEF was available for patient no. 6.</p><p>After 480&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX, the LVEF in patient no. 3 decreased to 53&#x00025;, which is a decline of 25&#x00025; compared to the LVEF before starting the study (71&#x00025;). The patient had no symptoms of cardiac failure. Ten months after his last cycle of chemotherapy, the LVEF remained stable and he remained without cardiac symptoms.</p><p>The LVEF of patient no. 4 showed an initial drop from 72&#x00025; before starting chemotherapy to 60&#x00025; after 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX (decline of &#x0003e;15&#x00025;). This value remained stable up to 450&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of DOX, and at 10-month follow-up the patient still had an excellent physical condition.</p></sec><sec><title>Evaluation of tumour response</title><p>Response to the chemotherapy was remarkable in the four patients with metastatic soft-tissue sarcoma (STS). Three of them developed a partial remission (PR), as observed on the CT scan (<xref rid="tbl1" ref-type="table">Table 1</xref>). In two of these patients (nos. 4 and 7), PR was maintained up to the present, that is, 30 and 16 months after the start of chemotherapy, respectively. The other patient (no. 3) had progressive disease after a PR of 9 months duration. The fourth patient (no. 8) achieved stable disease for at least 7 months, while continuing therapy with DOX up to a cumulative dose of 495&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>.</p></sec></sec><sec><title>DISCUSSION</title><p>On the basis of the promising results with monoHER observed in preclinical experiments, we performed the present phase II study in patients with metastatic cancer. The cardioprotective effect of monoHER on DOX-induced cardiotoxicity was evaluated by endomyocardial biopsy. However, the results indicated that the preclinical observations were not translated into protection against DOX-induced heart damage in humans.</p><p>The golden standard for early detection of DOX-induced cardiotoxicity is the endomyocardial biopsy, because of its high sensitivity and high specificity (<xref ref-type="other" rid="bib34">Torti <italic>et al</italic>, 1986</xref>). Currently, the most common method used to detect DOX-induced cardiac damage is the evaluation of the LVEF, but usually at later stages (<xref ref-type="other" rid="bib18">Kilickap <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib39">Villani <italic>et al</italic>, 2006</xref>). For detection of cardiotoxicity at an earlier stage, the use of biochemical markers such as atrial and brain natriuretic peptides, endothelin-1 and also cardiac troponin-T and -I have been investigated (<xref ref-type="other" rid="bib43">Yamashita <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib33">Suzuki <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib18">Kilickap <italic>et al</italic>, 2005</xref>). However, large-scale studies addressing whether these biomarkers following DOX treatment will be predictive for the development of late-onset heart failure are lacking. Therefore, despite its invasiveness, we chose the endomyocardial biopsy for this evaluation.</p><p>Data of <xref ref-type="other" rid="bib3">Billingham <italic>et al</italic> (1978)</xref> showed that anthracycline-induced myocardial damage occurred in nearly all patients treated with cumulative DOX doses of 240&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. Therefore, we could expect detectable heart damage after a cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, which would allow the registration of protection by monoHER. However, all five patients undergoing the biopsy procedure after a median cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> showed DOX-induced cardiotoxicity with a mean biopsy score of 2.7 according to <xref ref-type="other" rid="bib3">Billingham <italic>et al</italic> (1978)</xref>. This score was independent of the time interval between monoHER and DOX infusion and much higher than the biopsy score of 1.4, which is expected after a cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX according to the linear regression analysis of <xref ref-type="other" rid="bib34">Torti <italic>et al</italic> (1986)</xref>. In our patients, mainly one of the three morphological changes, that is, small vacuoles of varying size, was observed after 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX, whereas in Torti <italic>et al</italic>'s study also partial or total myofibrillar loss was observed. However, in Torti's study, it is not clear after which dose this occurred. In addition to microvacuolisation, loss of myofibrils was demonstrated in two patients after higher cumulative doses of DOX. This suggests that the occurrence of microvacuoles as such is a marker of cytotoxicity of DOX treatment. <xref ref-type="other" rid="bib2">Billingham <italic>et al</italic> (1977)</xref> described that these microvacuoles appear early as a swelling of the sarcoplasmic reticulum, which eventually coalesce to form large spaces in the cytoplasm (macrovacuoles). The possible change from microvacuoles into macrovacuoles in time is not clear from literature.</p><p>Thus, instead of protection, our patients had higher biopsy scores than the historical controls. However, it should be noted that the data of <xref ref-type="other" rid="bib34">Torti <italic>et al</italic> (1986)</xref> were obtained after a cumulative dose of 200&#x02013;300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> with biopsies from the right ventricle, whereas biopsies from our patients were obtained after a cumulative dose of 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> from the left ventricle. Previously, it was shown that ultrastructural abnormalities of cardiomyocytes were more pronounced in biopsy specimens from the left ventricle than those from the right ventricle (<xref ref-type="other" rid="bib24">Mortensen <italic>et al</italic>, 1986</xref>). In addition to this, there is a considerable variability in patient sensitivity to the cardiotoxic effects of DOX (<xref ref-type="other" rid="bib12">Ferrans 1978</xref>; <xref ref-type="other" rid="bib21">Mason <italic>et al</italic>, 1978</xref>). These data may explain a possible overestimation of the toxic effect of DOX on the heart tissue in our patients. Although heart failure is directly related to the degree of myocyte damage (<xref ref-type="other" rid="bib6">Bristow <italic>et al</italic>, 1978</xref>), none of our patients developed heart failure, although the LVEF dropped by 16&#x00025; in two patients, whereas it decreased in two other patients by only 4&#x02013;6&#x00025; (in comparison to the initial LVEF).</p><p>In the third biopsy procedure of patient no. 4, the score of the cardiac tissue had improved. A recuperation of myofibrils in the cardiomyocytes was observed and the microvacuolisation was less. These findings are in agreement with a previous study reporting that some improvement of the histological damage may occur (<xref ref-type="other" rid="bib20">Mackay <italic>et al</italic>, 1994</xref>). This is in contrast with other results, which indicated that DOX-induced cardiotoxicity is an ongoing progressive process (<xref ref-type="other" rid="bib3">Billingham <italic>et al</italic>, 1978</xref>).</p><p>The contrasting effects of monoHER found in animal and human studies may be attributed to differences in metabolism between the species. Therefore, patient no. 8 was treated with a 2&#x02009;h interval. However, this interval change did not reduce DOX-induced cardiotoxicity. In addition, no metabolites of monoHER have been detected until now. On the other hand, it cannot be excluded that during scavenging of the reactive oxygen species, the antioxidant monoHER is converted into a reactive oxidation product, which, like the oxidation product of quercetin, may be prone to form adducts with thiol groups from glutathione and proteins (<xref ref-type="other" rid="bib4">Boots <italic>et al</italic>, 2005a</xref>). Depletion of glutathione may in addition to the low antioxidant status of the cardiomyocyte (<xref ref-type="other" rid="bib25">Nowak and Drzwoski, 1996</xref>) reduce cardioprotection, while monoHER-protein adducts may cause additional toxicity (<xref ref-type="other" rid="bib5">Boots <italic>et al</italic>, 2005b</xref>).</p><p>Another unexpected observation in our study was that three of the four patients with STS had objective remissions, while the fourth patient had stable disease. Normally, objective responses on DOX in STS patients without prior chemotherapy are approximately 25&#x00025; (<xref ref-type="other" rid="bib27">Santoro <italic>et al</italic>, 1995</xref>). Although our observation was done in a very limited number of patients, our result is much better than expected, because the chance of observing an objective response in four consecutive STS patients treated with DOX is 0.4&#x00025;. Thus, it is suggestive that monoHER enhances the antitumour activity of DOX in STS.</p><p>This observation is in agreement with potentiating antitumour effects of a few flavonoids observed <italic>in vitro</italic> (<xref ref-type="other" rid="bib11">Elangovan <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib31">Sliutz <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib9">Debes <italic>et al</italic>, 2003</xref>). The background for this effect may be that the concentration of GSH may play a role in STS chemoresistance (<xref ref-type="other" rid="bib14">Hochwald <italic>et al</italic>, 1997</xref>) and that GSH depletion may increase the antitumour efficacy (<xref ref-type="other" rid="bib29">Siemann and Beyers, 1997</xref>). Thus, the same mechanism may play a role as hypothesised for the cardiomyocytes.</p><p>As a consequence of the above-mentioned aspects, there may be a dose-depending transition in the effect of monoHER, that is a high dose (&#x02a7e;1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) for obtaining a potentiating effect of the antitumour effect for at least STS and a low dose (somewhere below 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) for obtaining cardioprotection. These aspects have to be elucidated further in the near future. It may be concluded that monoHER at a dose of 1500&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> did not protect against DOX-induced cardiotoxicity in patients with metastatic disease, but may have an enhancing effect on the antitumour activity of DOX in patients with metastatic STS. Further preclinical and clinical investigations seem to be warranted to investigate the postulated dose-depending transitional effect of monoHER.</p></sec></body><back><ack><p>We thank Marike Rebel, Ellen Geerligs, Emine Torun and Jan Fritz for their excellent assistance. We are thankful for the skilful cooperation with the staff of the Department of Hospital Pharmacy, the Department of Medical Oncology, the Department of Cardiology and Department of Pathology, The VU University Medical Center, Amsterdam, The Netherlands. Finally, we are very grateful to the patients who participated in this study. This work was supported in part by Grant VU-97-1525 from the Koningin Wilhelmina Foundation, Amsterdam, The Netherlands.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abou El Hassan</surname><given-names>MAI</given-names></name><name><surname>Kedde</surname><given-names>MA</given-names></name><name><surname>Zwiers</surname><given-names>UTH</given-names></name><name><surname>Torun</surname><given-names>E</given-names></name><name><surname>Haenen</surname><given-names>GRMM</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>Van der Vijgh</surname><given-names>WJF</given-names></name></person-group><article-title>Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice</article-title><source>Cancer Chemother Pharmacol</source><year>2003</year><volume>52</volume><fpage>371</fpage><lpage>376</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||52|371||bib1|'--><pub-id pub-id-type="pmid">12898182</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Glatstein</surname><given-names>E</given-names></name><name><surname>Mason</surname><given-names>JW</given-names></name><name><surname>Masek</surname><given-names>MA</given-names></name><name><surname>Daniels</surname><given-names>JR</given-names></name></person-group><article-title>Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation</article-title><source>Am J Surg Pathol</source><year>1977</year><volume>1</volume><fpage>17</fpage><lpage>23</lpage><!--PubMed citation query: 'Am J Surg Pathol||1|17||bib2|'--><pub-id pub-id-type="pmid">602969</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>JW</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Daniels</surname><given-names>JR</given-names></name></person-group><article-title>Anthracycline cardiomyopathy monitored by morphologic changes</article-title><source>Cancer Treat Rep</source><year>1978</year><volume>62</volume><fpage>865</fpage><lpage>872</lpage><!--PubMed citation query: 'Cancer Treat Rep||62|865||bib3|'--><pub-id pub-id-type="pmid">667860</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boots</surname><given-names>AW</given-names></name><name><surname>Balk</surname><given-names>JM</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>Haenen</surname><given-names>GR</given-names></name></person-group><article-title>The reversibility of glutathionyl-quercetin adducts spreads oxidized quercetin-induced toxicity</article-title><source>Biochem Biophys Res Commun</source><year>2005a</year><volume>338</volume><fpage>923</fpage><lpage>929</lpage><!--PubMed citation query: 'Biochem Biophys Res Commun||338|923||bib4|'--><pub-id pub-id-type="pmid">16246300</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boots</surname><given-names>AW</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>Haenen</surname><given-names>GRMM</given-names></name></person-group><article-title>No role of DT-diaphorase (NQO1) in the protection against oxidized quercetin</article-title><source>FEBS Lett</source><year>2005b</year><volume>579</volume><fpage>677</fpage><lpage>682</lpage><!--PubMed citation query: 'FEBS Lett||579|677||bib5|'--><pub-id pub-id-type="pmid">15670828</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>JW</given-names></name><name><surname>Daniels</surname><given-names>JR</given-names></name></person-group><article-title>Clinical spectrum of anthracycline antibiotic cardiotoxicity</article-title><source>Cancer Treat Rep</source><year>1978</year><volume>62</volume><fpage>873</fpage><lpage>879</lpage><!--PubMed citation query: 'Cancer Treat Rep||62|873||bib6|'--><pub-id pub-id-type="pmid">667861</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Lopez</surname><given-names>MB</given-names></name><name><surname>Mason</surname><given-names>JW</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Winchester</surname><given-names>MA</given-names></name></person-group><article-title>Efficacy and cost of cardiac monitoring in patients receiving doxorubicin</article-title><source>Cancer</source><year>1982</year><volume>50</volume><fpage>32</fpage><lpage>41</lpage><!--PubMed citation query: 'Cancer||50|32||bib7|'--><pub-id pub-id-type="pmid">7083125</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cvetkovic</surname><given-names>RS</given-names></name><name><surname>Scott</surname><given-names>L</given-names><suffix>Jr</suffix></name></person-group><article-title>Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy</article-title><source>Drugs</source><year>2005</year><volume>65</volume><fpage>1005</fpage><lpage>1024</lpage><!--PubMed citation query: 'Drugs||65|1005||bib8|'--><pub-id pub-id-type="pmid">15892593</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Debes</surname><given-names>A</given-names></name><name><surname>Oerding</surname><given-names>M</given-names></name><name><surname>Willers</surname><given-names>R</given-names></name><name><surname>Gobel</surname><given-names>U</given-names></name><name><surname>Wessalowski</surname><given-names>R</given-names></name></person-group><article-title>Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><fpage>3359</fpage><lpage>3366</lpage><!--PubMed citation query: 'Anticancer Res||23|3359||bib9|'--><pub-id pub-id-type="pmid">12926076</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doroshow</surname><given-names>JH</given-names></name><name><surname>Locker</surname><given-names>GY</given-names></name><name><surname>Meyers</surname><given-names>CE</given-names></name></person-group><article-title>Enzymatic defenses of the mouse heart against reactive oxygen metabolites</article-title><source>J Clin Invest</source><year>1980</year><volume>65</volume><fpage>128</fpage><lpage>135</lpage><!--PubMed citation query: 'J Clin Invest||65|128||bib10|'--><pub-id pub-id-type="pmid">7350193</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elangovan</surname><given-names>V</given-names></name><name><surname>Sekar</surname><given-names>N</given-names></name><name><surname>Govindasamy</surname><given-names>S</given-names></name></person-group><article-title>Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis</article-title><source>Cancer Lett</source><year>1994</year><volume>87</volume><fpage>107</fpage><lpage>113</lpage><!--PubMed citation query: 'Cancer Lett||87|107||bib11|'--><pub-id pub-id-type="pmid">7954363</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrans</surname><given-names>VJ</given-names></name></person-group><article-title>Overview of cardiac pathology in relation to anthracycline cardiotoxicity</article-title><source>Cancer Treat Rep</source><year>1978</year><volume>62</volume><fpage>955</fpage><lpage>961</lpage><!--PubMed citation query: 'Cancer Treat Rep||62|955||bib12|'--><pub-id pub-id-type="pmid">352510</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haenen</surname><given-names>GRMM</given-names></name><name><surname>Jansen</surname><given-names>FP</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name></person-group><article-title>The antioxidant properties of five <italic>O</italic>-(beta-hydroxyethyl) rutosides of the flavonoid mixture Venoruton</article-title><source>Phlebology Suppl</source><year>1993</year><volume>1</volume><fpage>10</fpage><lpage>17</lpage><!--PubMed citation query: 'Phlebology Suppl||1|10||bib13|'--></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochwald</surname><given-names>SN</given-names></name><name><surname>Rose</surname><given-names>DM</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Burt</surname><given-names>ME</given-names></name></person-group><article-title>Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma</article-title><source>Ann Surg Oncol</source><year>1997</year><volume>4</volume><fpage>303</fpage><lpage>309</lpage><!--PubMed citation query: 'Ann Surg Oncol||4|303||bib14|'--><pub-id pub-id-type="pmid">9181229</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horenstein</surname><given-names>MS</given-names></name><name><surname>Van der Heide</surname><given-names>RS</given-names></name><name><surname>L'Ecuyer</surname><given-names>TJ</given-names></name></person-group><article-title>Molecular basis of anthracycline-induced cardiotoxicity and its prevention</article-title><source>Mol Gen Metab</source><year>2000</year><volume>71</volume><fpage>436</fpage><lpage>444</lpage><!--PubMed citation query: 'Mol Gen Metab||71|436||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hrdina</surname><given-names>R</given-names></name><name><surname>Gersl</surname><given-names>V</given-names></name><name><surname>Klimtova</surname><given-names>I</given-names></name><name><surname>Simunek</surname><given-names>T</given-names></name><name><surname>Machackova</surname><given-names>J</given-names></name><name><surname>Cerman</surname><given-names>J</given-names></name><name><surname>Suba</surname><given-names>P</given-names></name></person-group><article-title>Anthracycline-induced cardiotoxicity</article-title><source>Acta Medica</source><year>2000</year><volume>43</volume><fpage>75</fpage><lpage>82</lpage><!--PubMed citation query: 'Acta Medica||43|75||bib16|'--></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iarussi</surname><given-names>D</given-names></name><name><surname>Indolfi</surname><given-names>P</given-names></name><name><surname>Galderisi</surname><given-names>M</given-names></name><name><surname>Bossone</surname><given-names>E</given-names></name></person-group><article-title>Cardiac toxicity after anthracycline chemotherapy in childhood</article-title><source>Herz</source><year>2000</year><volume>25</volume><fpage>676</fpage><lpage>688</lpage><!--PubMed citation query: 'Herz||25|676||bib17|'--><pub-id pub-id-type="pmid">11141677</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kilickap</surname><given-names>S</given-names></name><name><surname>Barista</surname><given-names>I</given-names></name><name><surname>Akgul</surname><given-names>E</given-names></name><name><surname>Aytemir</surname><given-names>E</given-names></name><name><surname>Aksoyek</surname><given-names>S</given-names></name><name><surname>Aksoy</surname><given-names>S</given-names></name><name><surname>Celik</surname><given-names>I</given-names></name><name><surname>Kes</surname><given-names>S</given-names></name><name><surname>Tekuzman</surname><given-names>G</given-names></name></person-group><article-title>cTnT can be a useful marker for early detection of anthracycline cardiotoxicity</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>798</fpage><lpage>804</lpage><!--PubMed citation query: 'Ann Oncol||16|798||bib18|'--><pub-id pub-id-type="pmid">15774486</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipshultz</surname><given-names>SE</given-names></name><name><surname>Lipsitz</surname><given-names>SR</given-names></name><name><surname>Sallan</surname><given-names>SE</given-names></name><name><surname>Dalton</surname><given-names>VM</given-names></name><name><surname>Mone</surname><given-names>SM</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Colan</surname><given-names>SD</given-names></name></person-group><article-title>Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2629</fpage><lpage>2636</lpage><!--PubMed citation query: 'J Clin Oncol||23|2629||bib19|'--><pub-id pub-id-type="pmid">15837978</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>B</given-names></name><name><surname>Ewer</surname><given-names>MS</given-names></name><name><surname>Carrasco</surname><given-names>CH</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name></person-group><article-title>Assessment of anthracycline cardiomyopathy by endomyocardial biopsy</article-title><source>Ultrastruct Pathol</source><year>1994</year><volume>18</volume><fpage>203</fpage><lpage>211</lpage><!--PubMed citation query: 'Ultrastruct Pathol||18|203||bib20|'--><pub-id pub-id-type="pmid">8191628</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>JW</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Daniels</surname><given-names>JR</given-names></name></person-group><article-title>Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy</article-title><source>Cancer Treat Rep</source><year>1978</year><volume>62</volume><fpage>857</fpage><lpage>864</lpage><!--PubMed citation query: 'Cancer Treat Rep||62|857||bib21|'--><pub-id pub-id-type="pmid">667859</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meinardi</surname><given-names>M</given-names></name><name><surname>Van der Graaf</surname><given-names>W</given-names></name><name><surname>Van Veldhuisen</surname><given-names>DJ</given-names></name><name><surname>Gietema</surname><given-names>JA</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>Sleijfer</surname><given-names>DT</given-names></name></person-group><article-title>Detection of anthracycline-induced cardiotoxicity</article-title><source>Cancer Treat Rev</source><year>1999</year><volume>25</volume><fpage>237</fpage><lpage>247</lpage><!--PubMed citation query: 'Cancer Treat Rev||25|237||bib22|'--><pub-id pub-id-type="pmid">10448132</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minotti</surname><given-names>G</given-names></name><name><surname>Menna</surname><given-names>P</given-names></name><name><surname>Salvatorelli</surname><given-names>E</given-names></name><name><surname>Cairo</surname><given-names>G</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name></person-group><article-title>Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity</article-title><source>Pharmacol Rev</source><year>2004</year><volume>56</volume><fpage>185</fpage><lpage>229</lpage><!--PubMed citation query: 'Pharmacol Rev||56|185||bib23|'--><pub-id pub-id-type="pmid">15169927</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>SA</given-names></name><name><surname>Olsen</surname><given-names>HS</given-names></name><name><surname>Baandrup</surname><given-names>U</given-names></name></person-group><article-title>Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease</article-title><source>Br Heart J</source><year>1986</year><volume>55</volume><fpage>274</fpage><lpage>282</lpage><!--PubMed citation query: 'Br Heart J||55|274||bib24|'--><pub-id pub-id-type="pmid">3456785</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Drzwoski</surname><given-names>J</given-names></name></person-group><article-title>Anthracycline-induced oxidative stress &#x02013; its role in the development of cardiac damage</article-title><source>Cancer J</source><year>1996</year><volume>9</volume><fpage>296</fpage><lpage>303</lpage><!--PubMed citation query: 'Cancer J||9|296||bib25|'--></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oken</surname><given-names>MM</given-names></name><name><surname>Creech</surname><given-names>RH</given-names></name><name><surname>Tormey</surname><given-names>DC</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>TE</given-names></name><name><surname>McFadden</surname><given-names>ET</given-names></name><name><surname>Carbone</surname><given-names>PP</given-names></name></person-group><article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title><source>Am J Clin Oncol</source><year>1982</year><volume>5</volume><fpage>649</fpage><lpage>655</lpage><!--PubMed citation query: 'Am J Clin Oncol||5|649||bib26|'--><pub-id pub-id-type="pmid">7165009</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Tursz</surname><given-names>T</given-names></name><name><surname>Mouridsen</surname><given-names>H</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Steward</surname><given-names>W</given-names></name><name><surname>Somers</surname><given-names>R</given-names></name><name><surname>Buesa</surname><given-names>J</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name><name><surname>Spooner</surname><given-names>D</given-names></name><name><surname>Rankin</surname><given-names>E</given-names></name></person-group><article-title>Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1537</fpage><lpage>1545</lpage><!--PubMed citation query: 'J Clin Oncol||13|1537||bib27|'--><pub-id pub-id-type="pmid">7602342</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seidman</surname><given-names>A</given-names></name><name><surname>Hudis</surname><given-names>C</given-names></name><name><surname>Pierri</surname><given-names>MK</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><name><surname>Paton</surname><given-names>V</given-names></name><name><surname>Ashby</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Steward</surname><given-names>SJ</given-names></name><name><surname>Keefe</surname><given-names>D</given-names></name></person-group><article-title>Cardiac dysfunction in the trastuzumab clinical trials experience</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>1215</fpage><lpage>1221</lpage><!--PubMed citation query: 'J Clin Oncol||20|1215||bib28|'--><pub-id pub-id-type="pmid">11870163</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siemann</surname><given-names>DW</given-names></name><name><surname>Beyers</surname><given-names>KL</given-names></name></person-group><article-title><italic>In vivo</italic> therapeutic potential of combination thiol depletion and alkylating chemotherapy</article-title><source>Br J Cancer</source><year>1997</year><volume>68</volume><fpage>1071</fpage><lpage>1079</lpage><!--PubMed citation query: 'Br J Cancer||68|1071||bib29|'--><pub-id pub-id-type="pmid">8260357</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>C</given-names></name><name><surname>Ervin</surname><given-names>T</given-names></name><name><surname>Welles</surname><given-names>L</given-names></name><name><surname>Azarnia</surname><given-names>N</given-names></name><name><surname>Keating</surname><given-names>J</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name></person-group><article-title>Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1435</fpage><lpage>1441</lpage><!--PubMed citation query: 'J Clin Oncol||17|1435||bib30|'--><pub-id pub-id-type="pmid">10334528</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sliutz</surname><given-names>G</given-names></name><name><surname>Karlseder</surname><given-names>J</given-names></name><name><surname>Tempfer</surname><given-names>C</given-names></name><name><surname>Orel</surname><given-names>L</given-names></name><name><surname>Holzer</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>MM</given-names></name></person-group><article-title>Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression <italic>in vitro</italic>: implication of quercetin as sensitiser in chemotherapy</article-title><source>Br J Cancer</source><year>1996</year><volume>74</volume><fpage>172</fpage><lpage>177</lpage><!--PubMed citation query: 'Br J Cancer||74|172||bib31|'--><pub-id pub-id-type="pmid">8688318</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinherz</surname><given-names>LJ</given-names></name><name><surname>Steinherz</surname><given-names>PG</given-names></name><name><surname>Tan</surname><given-names>CTC</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>L</given-names></name></person-group><article-title>Cardiac toxicity 4 to 20 years after completing anthracyclin therapy</article-title><source>JAMA</source><year>2001</year><volume>266</volume><fpage>1672</fpage><lpage>1677</lpage><!--PubMed citation query: 'JAMA||266|1672||bib32|'--><pub-id pub-id-type="pmid">1886191</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>D</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>Y</given-names></name><name><surname>Komoro</surname><given-names>I</given-names></name><name><surname>Kurabayashi</surname><given-names>M</given-names></name><name><surname>Yamaoki</surname><given-names>K</given-names></name><name><surname>Mitani</surname><given-names>K</given-names></name><name><surname>Hirai</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Yazaki</surname><given-names>Y</given-names></name></person-group><article-title>Elevated B-type natriuretic peptide levels after anthracycline administration</article-title><source>Am Heart J</source><year>1998</year><volume>136</volume><fpage>362</fpage><lpage>363</lpage><!--PubMed citation query: 'Am Heart J||136|362||bib33|'--><pub-id pub-id-type="pmid">9704703</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torti</surname><given-names>FM</given-names></name><name><surname>Bristow</surname><given-names>MM</given-names></name><name><surname>Lum</surname><given-names>BL</given-names></name><name><surname>Carter</surname><given-names>SK</given-names></name><name><surname>Howes</surname><given-names>AE</given-names></name><name><surname>Aston</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>BW</given-names><suffix>Jr</suffix></name><name><surname>Hannigan</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Meyers</surname><given-names>FJ</given-names></name><name><surname>Mitchell</surname><given-names>EP</given-names></name></person-group><article-title>Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><fpage>3722</fpage><lpage>3727</lpage><!--PubMed citation query: 'Cancer Res||46|3722||bib34|'--><pub-id pub-id-type="pmid">3458531</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Acker</surname><given-names>FA</given-names></name><name><surname>van Acker</surname><given-names>SA</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Haenen</surname><given-names>GRMM</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>van der Vijgh</surname><given-names>WJF</given-names></name></person-group><article-title>7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>1337</fpage><lpage>1341</lpage><!--PubMed citation query: 'Clin Cancer Res||6|1337||bib35|'--><pub-id pub-id-type="pmid">10778960</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Acker</surname><given-names>SA</given-names></name><name><surname>Boven</surname><given-names>E</given-names></name><name><surname>Kuiper</surname><given-names>K</given-names></name><name><surname>van den Berg</surname><given-names>DJ</given-names></name><name><surname>Grimbergen</surname><given-names>JA</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>van der Vijgh</surname><given-names>WJ</given-names></name></person-group><article-title>Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1747</fpage><lpage>1754</lpage><!--PubMed citation query: 'Clin Cancer Res||3|1747||bib36|'--><pub-id pub-id-type="pmid">9815559</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Acker</surname><given-names>SA</given-names></name><name><surname>Towart</surname><given-names>R</given-names></name><name><surname>Husken</surname><given-names>BCP</given-names></name><name><surname>de Jong</surname><given-names>J</given-names></name><name><surname>van der Vijgh</surname><given-names>WJ</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name></person-group><article-title>The protective effect of Venoruton and its constituents on acute doxorubicin-induced cardiotoxicity</article-title><source>Phlebology</source><year>1993</year><volume>1</volume><fpage>31</fpage><lpage>32</lpage><!--PubMed citation query: 'Phlebology||1|31||bib37|'--></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dalen</surname><given-names>EC</given-names></name><name><surname>Caron</surname><given-names>HN</given-names></name><name><surname>Dickinson</surname><given-names>HO</given-names></name><name><surname>Kremer</surname><given-names>LC</given-names></name></person-group><article-title>Cardioprotective interventions for cancer patients receiving anthracyclines</article-title><source>The Cochrane Database of Systematic Reviews, Issue</source><year>2005</year><volume>1</volume><fpage>2005</fpage><!--PubMed citation query: 'The Cochrane Database of Systematic Reviews, Issue||1|2005||bib38|'--></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villani</surname><given-names>F</given-names></name><name><surname>Meazza</surname><given-names>R</given-names></name><name><surname>Materazzo</surname><given-names>C</given-names></name></person-group><article-title>Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>797</fpage><lpage>801</lpage><!--PubMed citation query: 'Anticancer Res||26|797||bib39|'--><pub-id pub-id-type="pmid">16739356</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>AM</given-names></name><name><surname>Bruynzeel</surname><given-names>AME</given-names></name><name><surname>Kedde</surname><given-names>MA</given-names></name><name><surname>van Groeningen</surname><given-names>CJ</given-names></name><name><surname>Bast</surname><given-names>A</given-names></name><name><surname>van der Vijgh</surname><given-names>WJ</given-names></name></person-group><article-title>A phase I study of monohydroxyethylrutoside in healthy volunteers</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>57</volume><fpage>678</fpage><lpage>684</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||57|678||bib40|'--><pub-id pub-id-type="pmid">16136309</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wouters</surname><given-names>KA</given-names></name><name><surname>Kremer</surname><given-names>LC</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Herman</surname><given-names>EH</given-names></name><name><surname>Lipshultz</surname><given-names>SE</given-names></name></person-group><article-title>Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies</article-title><source>Br J Haematol</source><year>2005</year><volume>131</volume><fpage>561</fpage><lpage>578</lpage><!--PubMed citation query: 'Br J Haematol||131|561||bib41|'--><pub-id pub-id-type="pmid">16351632</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>MF</given-names></name><name><surname>Tang</surname><given-names>PL</given-names></name><name><surname>Qian</surname><given-names>ZM</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name></person-group><article-title>Effects by doxorubicin on the myocardium are mediated by oxygen free radicals</article-title><source>Life Sci</source><year>2001</year><volume>68</volume><fpage>889</fpage><lpage>901</lpage><!--PubMed citation query: 'Life Sci||68|889||bib42|'--><pub-id pub-id-type="pmid">11213359</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>J</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Shirakusa</surname><given-names>T</given-names></name></person-group><article-title>Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity</article-title><source>Int J Cancer</source><year>1995</year><volume>62</volume><fpage>542</fpage><lpage>547</lpage><!--PubMed citation query: 'Int J Cancer||62|542||bib43|'--><pub-id pub-id-type="pmid">7665224</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Heart tissue from patient no. 3 after 300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX. Evaluation by electron microscopy demonstrated an abundant presence of microvacuoles in the cardiomyocytes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="tiff" xlink:href="6603994f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Heart tissue from patient no. 3 after 480&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> DOX. In addition to the vacuolisation, a loss of myofibrils is observed with electron microscopy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="tiff" xlink:href="6603994f2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="center"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patient no.</bold></th><th align="left" valign="top" charoff="50"><bold>Age&#x0002f;sex</bold></th><th align="left" valign="top" charoff="50"><bold>Diagnosis</bold></th><th align="center" valign="top" charoff="50"><bold>Total dose of DOX (mg&#x02009;m<sup>&#x02212;2</sup>)</bold></th><th align="left" valign="top" charoff="50"><bold>Response on DOX</bold></th><th align="left" valign="top" charoff="50"><bold>Biopsy</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">01</td><td align="left" valign="top" charoff="50">62&#x0002f;F</td><td align="left" valign="top" charoff="50">Breast cancer</td><td align="center" valign="top" charoff="50">100</td><td align="left" valign="top" charoff="50">PD</td><td align="left" valign="top" charoff="50">N</td></tr><tr><td align="left" valign="top" charoff="50">02</td><td align="left" valign="top" charoff="50">54&#x0002f;F</td><td align="left" valign="top" charoff="50">Adrenal cortical cancer</td><td align="center" valign="top" charoff="50">150</td><td align="left" valign="top" charoff="50">PD</td><td align="left" valign="top" charoff="50">N</td></tr><tr><td align="left" valign="top" charoff="50">03</td><td align="left" valign="top" charoff="50">25&#x0002f;M</td><td align="left" valign="top" charoff="50">Malignant peripheral nerve sheet tumour</td><td align="center" valign="top" charoff="50">480</td><td align="left" valign="top" charoff="50">PR</td><td align="left" valign="top" charoff="50">Y</td></tr><tr><td align="left" valign="top" charoff="50">04</td><td align="left" valign="top" charoff="50">64&#x0002f;M</td><td align="left" valign="top" charoff="50">Malignant fibrous histiocytoma</td><td align="center" valign="top" charoff="50">450</td><td align="left" valign="top" charoff="50">PR</td><td align="left" valign="top" charoff="50">Y</td></tr><tr><td align="left" valign="top" charoff="50">05</td><td align="left" valign="top" charoff="50">55&#x0002f;F</td><td align="left" valign="top" charoff="50">Breast cancer</td><td align="center" valign="top" charoff="50">100</td><td align="left" valign="top" charoff="50">PD</td><td align="left" valign="top" charoff="50">N</td></tr><tr><td align="left" valign="top" charoff="50">06</td><td align="left" valign="top" charoff="50">48&#x0002f;F</td><td align="left" valign="top" charoff="50">Breast cancer</td><td align="center" valign="top" charoff="50">300</td><td align="left" valign="top" charoff="50">SD</td><td align="left" valign="top" charoff="50">Y</td></tr><tr><td align="left" valign="top" charoff="50">07</td><td align="left" valign="top" charoff="50">45&#x0002f;F</td><td align="left" valign="top" charoff="50">Malignant fibrous histiocytoma</td><td align="center" valign="top" charoff="50">300</td><td align="left" valign="top" charoff="50">PR</td><td align="left" valign="top" charoff="50">Y</td></tr><tr><td align="left" valign="top" charoff="50">08</td><td align="left" valign="top" charoff="50">56&#x0002f;F</td><td align="left" valign="top" charoff="50">Malignant fibrous histiocytoma</td><td align="center" valign="top" charoff="50">375</td><td align="left" valign="top" charoff="50">SD</td><td align="left" valign="top" charoff="50">Y</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>Age in years; sex F female, M male; assessment of tumour response was done by using standard ECOG criteria (PD&#x0003d;progressive disease; PR&#x0003d;partial remission; SD&#x0003d;stable disease); Y&#x0003d;yes; N&#x0003d;no.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Patients who received at least a cumulative dose (cum. dose) of 300&#x02009;mg&#x02009;m<sup>2</sup> DOX and underwent an endomyocardial biopsy</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patient no.</bold></th><th align="left" valign="top" charoff="50"><bold>Biopsy score cum. dose (no. of cycles &#x000d7; dose per cycle, time of bolus infusion&#x0002f;&#x00394;<italic>t</italic>&#x0002f;grade</bold></th><th align="center" valign="top" charoff="50"><bold>LVEF before dox</bold></th><th align="center" valign="top" charoff="50"><bold>LVEF after &#x02a7e;300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">03</td><td align="left" valign="top" charoff="50">300 (4 &#x000d7; 75, 15&#x02032;)&#x0002f;60&#x0002f;grade 3</td><td align="center" valign="top" charoff="50">71&#x00025;</td><td align="center" valign="top" charoff="50">67&#x00025;</td></tr><tr><td align="left" valign="top" charoff="50">04</td><td align="left" valign="top" charoff="50">300 (4 &#x000d7; 75, 15&#x02032;)&#x0002f;60&#x0002f;grade 2</td><td align="center" valign="top" charoff="50">72&#x00025;</td><td align="center" valign="top" charoff="50">60&#x00025;</td></tr><tr><td align="left" valign="top" charoff="50">06</td><td align="left" valign="top" charoff="50">300 (6 &#x000d7; 50, 15&#x02032;)&#x0002f;60&#x0002f;grade 2.5</td><td align="center" valign="top" charoff="50">52&#x00025;</td><td align="center" valign="top" charoff="50">ND</td></tr><tr><td align="left" valign="top" charoff="50">07</td><td align="left" valign="top" charoff="50">300 (4 &#x000d7; 75, 15&#x02032;)&#x0002f;10&#x0002f;grade 3</td><td align="center" valign="top" charoff="50">75&#x00025;</td><td align="center" valign="top" charoff="50">63&#x00025;</td></tr><tr><td align="left" valign="top" charoff="50">08</td><td align="left" valign="top" charoff="50">375 (5 &#x000d7; 75, 15&#x02032;)&#x0002f;120&#x0002f;grade 3</td><td align="center" valign="top" charoff="50">65&#x00025;</td><td align="center" valign="top" charoff="50">63&#x00025;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>&#x00394;<italic>t</italic>&#x0003d;time between end of monoHER infusion and start of DOX infusion in minutes.</p></fn><fn id="t2-fn2"><label/><p>The morphological grade was scored on a six-point scale previously described by Billingham and Bristow; LVEF&#x0003d;left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Two patients who underwent an extra endomyocardial biopsy at &#x0003e;300&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of DOX</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patient no.</bold></th><th align="center" valign="top" charoff="50"><bold>Cum.dose&#x0002f;biopsy score&#x0002f;LVEF</bold></th><th align="center" valign="top" charoff="50"><bold>Biopsy score&#x0002f;LVEF 10 months after the last cycle</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">03</td><td align="center" valign="top" charoff="50">480&#x0002f;grade 3&#x0002f;53&#x00025;</td><td align="center" valign="top" charoff="50">ND&#x0002f;51&#x00025;</td></tr><tr><td align="left" valign="top" charoff="50">04</td><td align="center" valign="top" charoff="50">450&#x0002f;grade 2.5&#x0002f;66&#x00025;</td><td align="center" valign="top" charoff="50">Grade 2&#x0002f;62&#x00025;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><label/><p>The morphological grade was scored on a six-point scale previously described by Billingham and Bristow; LVEF&#x0003d;left ventricular ejection fraction; ND&#x0003d;not done.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


